Quick generic drug news for today. If you or a loved one suffers from nerve pain (for example, as a result of diabetes or shingles), it’s bad news. Pfizer has won its a lawsuit against Apotex Inc. and other generic drug manufacturers to stop their generic versions of nerve pain drug Lyrica. Pfizer had filed the lawsuit against Apotex in U.S. District Court for the District of Delaware, accusing the generic drug company of infringing three Lyrica patents.
Pfizer said in a written statement: “With this decision, Pfizer will exclusively provide pregabalin as Lyrica to patients through December 30, 2018, in the U.S., pending generic company appeal and further litigation.”
The Food and Drug Administration has approved Lyrica to treat Diabetic Nerve Pain, Pain after Shingles, and Fibromyalgia. Lyrica has also been approved to treat Partial Onset Seizures in adults with epilepsy who take 1 or more drugs for seizures.
Considering a thirty-day supply of brand-name Lyrica is currently running almost $90, a generic version of Lyrica could easily have been a major savings for many diabetics, epileptics and fibromyalgia patients. We know lots of folks were hoping for better news, so you can be sure we’ll keeping an eye on when a generic version of Lyrica will finally be able to hit the market!
- Generic Drug News: Pfizer Files Lawsuit to Block Generic Version of Pain Drug Lyrica
- Generic Drug News: Endo Files Lawsuit to Block Generic Version of Migraine Drug Frova
- Generic Drug News: Sandoz Files Suit to Release Generic Version of Diabetes Drug Prandin
- Pfizer Files Lawsuit to Block Low-Cost, Generic Lipitor… When Will Generic Lipitor Hit the Market?
- Generic Lipitor News: Pfizer Settles Lawsuit Over Generic Lipitor